Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

OBJECTIVES: Pembrolizumab monotherapy showed significantly longer overall survival and fewer treatment-related adverse events compared to chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1)–positive tumors in the first-line s...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Min, Pietanza, M. Catherine, Samkari, Ayman, Pellissier, James, Burke, Thomas, Chandwani, Sheenu, Kong, Fansen, Pickard, A. Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323104/
https://www.ncbi.nlm.nih.gov/pubmed/30515719
http://dx.doi.org/10.1007/s40273-018-0752-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323104/
https://www.ncbi.nlm.nih.gov/pubmed/30515719
http://dx.doi.org/10.1007/s40273-018-0752-0

Ejemplares similares